International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1295-1301 , 1 August 2008

In Patients Experiencing Biochemical Failure After Radiotherapy, Pretreatment Risk Group and PSA Velocity Predict Differences in Overall Survival and Biochemical Failure-Free Interval

  • Daniel E. Soto, M.D., M.S.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationReprint requests to: Daniel E. Soto, M.D., M.S., Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Dr., B2 C490, Box 0010, Ann Arbor, MI 48109-0010. Tel: (734) 936-4288; Fax (734) 763-7370
    • ,
  • Rebecca R. Andridge, M.S.

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI
    • ,
  • Charlie C. Pan, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Scott G. Williams, F.R.A.N.Z.C.R.

      Affiliations

    • Division of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VC, Australia
    • ,
  • Jeremy M.G. Taylor, Ph.D.

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI
    • ,
  • Howard M. Sandler, M.D., M.S.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

Received 12 January 2008 ,Revised 27 February 2008 ,Accepted 29 February 2008.

  • Image Result

    Biochemical failure-free interval. All patients had eventual biochemical failure using prostate-specific antigen nadir plus 2 ng/mL. Patients grouped by low risk and pretreatment prostate-specific ant

    Biochemical failure-free interval. All patients had eventual biochemical failure using prostate-specific antigen nadir plus 2 ng/mL. Patients grouped by low risk and pretreatment prostate-specific antigen velocity of ≤2 ng/mL vs. patients with either prostate-specific antigen velocity >2 ng/mL or high/intermediate-risk features (p = 0.04).

  • Image Result
    Overall survival. All patients had eventual biochemical failure using prostate-specific antigen nadir plus 2 ng/mL. Patients grouped by low risk and prostate-specific antigen velocity of ≤2 ng/mL vs.

    Overall survival. All patients had eventual biochemical failure using prostate-specific antigen nadir plus 2 ng/mL. Patients grouped by low risk and prostate-specific antigen velocity of ≤2 ng/mL vs. patients with either prostate-specific antigen velocity >2 ng/mL or high/intermediate-risk features (p = 0.02).

 Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

 Conflict of interest: none.

PII: S0360-3016(08)00503-8

doi: 10.1016/j.ijrobp.2008.02.069

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1295-1301 , 1 August 2008

Article Tools

* Image Usage & Resolution